Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

Clinical trial NCT07063329 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07063329
Sponsor: Avistone Pharmaceutical（Ningbo）Co., LTD.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)

Start date: 2025-08-08
Primary completion: 2028-03-08
Enrollment: 108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.